These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 1795492

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE.
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [Abstract] [Full Text] [Related]

  • 3. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
    Thiébaud D, Jaeger P, Jacquet AF, Burckhardt P.
    J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
    [Abstract] [Full Text] [Related]

  • 4. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
    Wimalawansa SJ.
    Cancer; 1994 Apr 15; 73(8):2223-30. PubMed ID: 8156530
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
    Oiso Y, Tomita A, Hasegawa H, Ariyoshi Y, Niinomi M, Yamamoto M, Takano T, Sakiyama N.
    Endocr J; 1994 Dec 15; 41(6):655-61. PubMed ID: 7704089
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S, Tisell LE, Lindstedt G, Lundberg PA.
    Surgery; 1991 Sep 15; 110(3):480-6. PubMed ID: 1845370
    [Abstract] [Full Text] [Related]

  • 10. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P, Thiébaud D, Perey L, von Fliedner V.
    Recent Results Cancer Res; 1989 Sep 15; 116():54-66. PubMed ID: 2762665
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
    Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP.
    Cancer J; 2006 Sep 15; 12(1):47-53. PubMed ID: 16613662
    [Abstract] [Full Text] [Related]

  • 13. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
    Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, Tauer K, Neidhart J, Mallette LE, Siegel R.
    J Clin Oncol; 1992 Jan 15; 10(1):134-42. PubMed ID: 1727915
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia.
    Wüster C, Schöter KH, Thiébaud D, Manegold C, Krahl D, Clemens MR, Ghielmini M, Jaeger P, Scharla SH.
    Bone Miner; 1993 Aug 15; 22(2):77-85. PubMed ID: 8251767
    [Abstract] [Full Text] [Related]

  • 16. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ, Dumon JC.
    Ann Oncol; 1994 Apr 15; 5(4):359-63. PubMed ID: 8075034
    [Abstract] [Full Text] [Related]

  • 17. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
    Young G, Shende A.
    Med Pediatr Oncol; 1998 Feb 15; 30(2):117-21. PubMed ID: 9403021
    [Abstract] [Full Text] [Related]

  • 18. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
    Tal A, Graves L.
    South Med J; 1996 Jun 15; 89(6):637-40. PubMed ID: 8638211
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia.
    Sleeboom HP, Bijvoet OL, van Oosterom AT, Gleed JH, O'Riordan JL.
    Lancet; 1983 Jul 30; 2(8344):239-43. PubMed ID: 6135076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.